Lung Cancer

ProMune shows improved responses in lung cancer

Published in Cancer Weekly, July 6th, 2004

Coley Pharmaceutical Group, Inc., announced interim results from a randomized, multicenter phase II clinical study evaluating the effects of the company's lead TLR Therapeutic, ProMune (CPG 7909), combined with chemotherapy compared to standard chemotherapy alone in first-line treatment of advanced non-small cell lung cancer (NSCLC).

Objective tumor responses (by RECIST) in 48 patients after four cycles of taxane/platinum were documented in 42% of 31 patients given ProMune combination versus 24% of 17 patients given chemotherapy alone. The primary tumor response endpoints were supported by interim progression-free survival curves and CT tumor measurements.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry